British Columbia Expands Use of Biosimilars to Explore Treatment Options

British Columbia Expands Use of Biosimilars to Explore Treatment Options

Shots:

  • BC decided to switch from reference product to biosimilars within 6 months, for patients suffering from diabetes, ankylosing spondylitis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis
  • Post Nov 25,2019 PharmaCare, a publicly funded national drug coverage program will no longer be providing coverage for the biologic products excluding some exceptional cases and patients receiving Enbrel, Remicade and Lantus will switch to Eticovo, Renflexis and Basaglar respectively
  • BC plans to save $96.6B in first three years and the decision is in practice with the listing of Jardiance and Taltz drug for diabetes and psoriatic arthritis respectively

Click here to read full press release/ article | Ref: British Columbia | Image: LinkedIn